An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice

Yvette I. Sheline, Tim West, Kevin Yarasheski, Robert Swarm, Mateusz S. Jasielec, Jonathan R. Fisher, Whitney D. Ficker, Ping Yan, Chengjie Xiong, Christine Frederiksen, Monica V. Grzelak, Robert Chott, Randall J. Bateman, John C. Morris, Mark A. Mintun, Jin-Moo Lee and John R. Cirrito: 2014 Sci Transl Med, 10.1126/scitranslmed.3008169 Read More

Abstract

Serotonin signaling suppresses generation of amyloid-β (Aβ) in vitro and in animal models of Alzheimer’s disease (AD). We show that in an aged transgenic AD mouse model (APP/PS1 plaque-bearing mice), the antidepressant citalopram, a selective serotonin reuptake inhibitor, decreased Aβ in brain interstitial fluid in a dose-dependent manner. Growth of individual amyloid plaques was assessed in plaque-bearing mice that were chronically administered citalopram. Citalopram arrested the growth of preexisting plaques and reduced the appearance of new plaques by 78%. In healthy human volunteers, citalopram’s effects on Aβ production and Aβ concentrations in cerebrospinal fluid (CSF) were measured prospectively using stable isotope labeling kinetics, with CSF sampling during acute dosing of citalopram. Aβ production in CSF was slowed by 37% in the citalopram group compared to placebo. This change was associated with a 38% decrease in total CSF Aβ concentrations in the drug-treated group. The ability to safely decrease Aβ concentrations is potentially important as a preventive strategy for AD. This study demonstrates key target engagement for future AD prevention trials.

Full Text

.

Posted on June 28, 2017
Posted in: HPAN, Lysosome, Neurodegeneration, Neurogenetics & Transcriptomics, Neurovascular Injury & Repair, Pilot Projects, Publications Authors: , , ,